<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04755348</url>
  </required_header>
  <id_info>
    <org_study_id>BAT2221030</org_study_id>
    <nct_id>NCT04755348</nct_id>
  </id_info>
  <brief_title>A Study to Assess the Pharmacokinetics of Oral Nicotine Pouches and Lozenges in Healthy Adults</brief_title>
  <official_title>A Single Dose, Randomised, Crossover Study to Assess the Pharmacokinetics of Oral Nicotine Pouches and Lozenges in Healthy Adults</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>British American Tobacco (Investments) Limited</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>British American Tobacco (Investments) Limited</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a randomised, open-label, confined, cross-over study to evaluate the nicotine&#xD;
      pharmacokinetics (PK) of modern oral nicotine pouches and nicotine lozenges carried out in 36&#xD;
      healthy adult subjects who smoke cigarettes and who may have experience using smokeless&#xD;
      tobacco (loose or pouches).&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Starting on Day 1, subjects will check-in at the clinical site to complete procedures to&#xD;
      confirm eligibility. Following basic check-in procedures (e.g., urine pregnancy test, urine&#xD;
      drug screen, alcohol test and vital signs), subjects will continue with a 7-day confinement.&#xD;
      Subjects will be randomized to a product sequence (using a Williams design).&#xD;
&#xD;
      Test sessions will occur every day during the remainder of the study. The active period of&#xD;
      each test session will last for approximately 4 hours after the start of Investigational&#xD;
      Product (IP) use. During each test session, a subject will be required to use their&#xD;
      randomized IP and during the session, PK blood draws and a subjective effects questionnaire&#xD;
      will be collected.&#xD;
&#xD;
      The day prior to each test session, subjects will participate in a product familiarization&#xD;
      period in which they will use one pouch or lozenge of their randomized IP. The product&#xD;
      familiarization period will occur after the scheduled test session (or after enrollment and&#xD;
      randomization on Day 1) and before the 12-hour tobacco and nicotine abstinence period.&#xD;
      Subjects should use the IP pouch for at least 30 minutes or allow the lozenge to dissolve&#xD;
      slowly.&#xD;
&#xD;
      Subjects will provide usual brand (UB) cigarettes for use during study confinement and have&#xD;
      access to their UB cigarettes for ad libitum use with the exception of 1) during the test&#xD;
      session, 2) during the the minimum 12-hour tobacco and nicotine abstinence period prior to&#xD;
      each test session and 3) a minimum of one hour after IP use during the product&#xD;
      familiarization period. Each UB cigarette must be requested from site staff and used butts&#xD;
      returned to site staff for accountability.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">February 18, 2021</start_date>
  <completion_date type="Actual">March 25, 2021</completion_date>
  <primary_completion_date type="Actual">March 20, 2021</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Other</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Cmax</measure>
    <time_frame>240 minutes</time_frame>
    <description>Maximum baseline-adjusted plasma concentration of nicotine</description>
  </primary_outcome>
  <primary_outcome>
    <measure>AUC0-240 mins</measure>
    <time_frame>0-240 minutes</time_frame>
    <description>Baseline-adjusted area under the plasma nicotine concentration-versus-time curve from time zero to 240 minutes after the start of IP use</description>
  </primary_outcome>
  <number_of_arms>6</number_of_arms>
  <enrollment type="Actual">36</enrollment>
  <condition>Tobacco Use</condition>
  <condition>Tobacco Smoking</condition>
  <condition>Cigarette Smoking</condition>
  <arm_group>
    <arm_group_label>Product usage order ABFCED</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects will use each of the 6 products (ABFCED) during an familiarization period, followed by a 4 hour Test Session</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Product usage order BCADFE</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects will use each of the 6 products (ABECD) during an familiarization period, followed by a 4 hour Test Session</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Product usage order CDBEAF</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects will use each of the 6 products (CDBEAF) during an familiarization period, followed by a 4 hour Test Session</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Product usage order DECFBA</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects will use each of the 6 products (DECFBA) during an familiarization period, followed by a 4 hour Test Session</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Product usage order EFDACB</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects will use each of the 6 products (EFDACB) during an familiarization period, followed by a 4 hour Test Session</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Product usage order FAEBDC</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects will use each of the 6 products (FAEBDC) during an familiarization period, followed by a 4 hour Test Session</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Product A</intervention_name>
    <description>A 4mg nicotine pouch product</description>
    <arm_group_label>Product usage order ABFCED</arm_group_label>
    <arm_group_label>Product usage order BCADFE</arm_group_label>
    <arm_group_label>Product usage order CDBEAF</arm_group_label>
    <arm_group_label>Product usage order DECFBA</arm_group_label>
    <arm_group_label>Product usage order EFDACB</arm_group_label>
    <arm_group_label>Product usage order FAEBDC</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Product B</intervention_name>
    <description>A 4mg nicotine pouch product</description>
    <arm_group_label>Product usage order ABFCED</arm_group_label>
    <arm_group_label>Product usage order BCADFE</arm_group_label>
    <arm_group_label>Product usage order CDBEAF</arm_group_label>
    <arm_group_label>Product usage order DECFBA</arm_group_label>
    <arm_group_label>Product usage order EFDACB</arm_group_label>
    <arm_group_label>Product usage order FAEBDC</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Product C</intervention_name>
    <description>A 2mg nicotine lozenge product</description>
    <arm_group_label>Product usage order ABFCED</arm_group_label>
    <arm_group_label>Product usage order BCADFE</arm_group_label>
    <arm_group_label>Product usage order CDBEAF</arm_group_label>
    <arm_group_label>Product usage order DECFBA</arm_group_label>
    <arm_group_label>Product usage order EFDACB</arm_group_label>
    <arm_group_label>Product usage order FAEBDC</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Product D</intervention_name>
    <description>A 2mg nicotine lozenge product</description>
    <arm_group_label>Product usage order ABFCED</arm_group_label>
    <arm_group_label>Product usage order BCADFE</arm_group_label>
    <arm_group_label>Product usage order CDBEAF</arm_group_label>
    <arm_group_label>Product usage order DECFBA</arm_group_label>
    <arm_group_label>Product usage order EFDACB</arm_group_label>
    <arm_group_label>Product usage order FAEBDC</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Product E</intervention_name>
    <description>A 2mg nicotine lozenge product</description>
    <arm_group_label>Product usage order ABFCED</arm_group_label>
    <arm_group_label>Product usage order BCADFE</arm_group_label>
    <arm_group_label>Product usage order CDBEAF</arm_group_label>
    <arm_group_label>Product usage order DECFBA</arm_group_label>
    <arm_group_label>Product usage order EFDACB</arm_group_label>
    <arm_group_label>Product usage order FAEBDC</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Product F</intervention_name>
    <description>A 2mg nicotine lozenge product</description>
    <arm_group_label>Product usage order ABFCED</arm_group_label>
    <arm_group_label>Product usage order BCADFE</arm_group_label>
    <arm_group_label>Product usage order CDBEAF</arm_group_label>
    <arm_group_label>Product usage order DECFBA</arm_group_label>
    <arm_group_label>Product usage order EFDACB</arm_group_label>
    <arm_group_label>Product usage order FAEBDC</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Able to read, understand, and willing to sign an informed consent form (ICF) and&#xD;
             complete questionnaires written in English.&#xD;
&#xD;
          2. Generally healthy males or females, 21 to 60 years of age, inclusive, at the time of&#xD;
             consent.&#xD;
&#xD;
          3. Smoke manufactured combustible, filtered, non-menthol or menthol cigarettes, 83 mm to&#xD;
             100 mm in length as primary source of tobacco.&#xD;
&#xD;
          4. Smokers who self-report use of a smokeless tobacco product (loose or pouch) prior to&#xD;
             screening may also be enrolled.&#xD;
&#xD;
          5. Smokes an average of at least 10 cigarettes per day (CPD) and inhale the smoke, for at&#xD;
             least 6 months prior to screening. Brief periods of abstinence due to illness, quit&#xD;
             attempt (prior to 30 days of screening), or clinical study participation (prior to 30&#xD;
             days of screening) will be allowed at the discretion of an investigator.&#xD;
&#xD;
          6. Agrees to smoke the same Usual Brand (UB) cigarette throughout the study period. The&#xD;
             UB cigarette is defined as the reported cigarette brand and style currently smoked&#xD;
             most frequently by the subject. If a subject reports use of a different UB cigarette&#xD;
             at check in, that subject may continue provided they use that same UB cigarette&#xD;
             throughout the study.&#xD;
&#xD;
          7. Expired breath carbon monoxide (ECO) level is ≥ 10 ppm and ≤ 100 ppm at screening.&#xD;
&#xD;
          8. Positive urine cotinine test at screening.&#xD;
&#xD;
          9. Willing to use the UB cigarette and nicotine pouch or lozenge IPs during the study&#xD;
             period.&#xD;
&#xD;
         10. Willing to abstain from tobacco and nicotine use for at least 12 hours prior to start&#xD;
             of each of six test sessions.&#xD;
&#xD;
         11. If female and of non-childbearing potential, must meet one of the following criteria:&#xD;
&#xD;
               1. Surgically sterile (i.e., has undergone complete hysterectomy, bilateral&#xD;
                  oophorectomy, or tubal ligation/occlusion); or&#xD;
&#xD;
               2. In a menopausal state (at least 1 year without menses), as confirmed by follicle&#xD;
                  stimulating hormone (FSH) levels (≥40 mIU/mL).&#xD;
&#xD;
         12. If female and of childbearing potential, must agree to use one of the accepted&#xD;
             contraceptive regimens from at least 30 days prior to the first administration of the&#xD;
             IP during the study, and for at least 30 days after the last dose of the IP. An&#xD;
             acceptable method of contraception includes one of the following:&#xD;
&#xD;
               1. Abstinence from heterosexual intercourse;&#xD;
&#xD;
               2. Hormonal contraceptives (birth control pills, injectable/implant/insertable&#xD;
                  hormonal birth control products, transdermal patch);&#xD;
&#xD;
               3. Intrauterine device (with or without hormones); or&#xD;
&#xD;
               4. Use of a double barrier method (e.g., condom and spermicide) during the study and&#xD;
                  for at least 30 days after the last dose of the study medication.&#xD;
&#xD;
         13. Agrees to an in-clinic confinement of 7 days (6 nights).&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Presence of clinically significant uncontrolled cardiovascular, pulmonary, renal,&#xD;
             hepatic, endocrine, gastrointestinal, psychiatric, hematological, neurological&#xD;
             disease, or any other concurrent disease or medical condition that, in the opinion of&#xD;
             an investigator, makes the study subject unsuitable to participate in this clinical&#xD;
             study.&#xD;
&#xD;
          2. History, presence of, or clinical laboratory test results indicating diabetes.&#xD;
&#xD;
          3. Scheduled treatment for asthma currently or within the past consecutive 12 months&#xD;
             prior to the screening visit. As-needed treatment, such as inhalers, may be included&#xD;
             at an investigator's discretion pending approval from the Medical Monitor.&#xD;
&#xD;
          4. History or presence of bleeding or clotting disorders.&#xD;
&#xD;
          5. Any history of cancer, except for primary cancers of skin such as localized basal&#xD;
             cell/squamous cell carcinoma that has been surgically and/or cryogenically removed.&#xD;
&#xD;
          6. Systolic blood pressure of &gt; 160 mmHg or a diastolic blood pressure of &gt; 95 mmHg,&#xD;
             measured after being seated for five minutes at screening and at check-in Day 1.&#xD;
&#xD;
          7. Weight of ≤ 110 pounds.&#xD;
&#xD;
          8. Hemoglobin level is &lt; 12.5 g/dL for females or &lt;13.0 g/dL for males at screening.&#xD;
&#xD;
          9. Females who have a positive pregnancy test, are pregnant, breastfeeding, or intend to&#xD;
             become pregnant during the course of the study.&#xD;
&#xD;
         10. Positive urine drug screen without evidence of a prescription or urine alcohol test at&#xD;
             Day 1 (check-in), with the exception of for tetrahydrocannabinol (THC). If positive&#xD;
             for THC, a cannabis intoxication evaluation will be performed at check-in, and&#xD;
             inclusion will be at the discretion of an investigator.&#xD;
&#xD;
         11. Positive test for human immunodeficiency virus (HIV), hepatitis B surface antigen&#xD;
             (HBsAg), or hepatitis C virus (HCV).&#xD;
&#xD;
         12. Self reports use of the study IP (nicotine pouches or lozenges) currently or in the&#xD;
             past.&#xD;
&#xD;
         13. Recreationally uses vapor products (e.g., e-cigarettes, tank systems) more than one&#xD;
             day per week, for the past 6 months prior to screening.&#xD;
&#xD;
         14. Current, regular user (i.e., &gt; 5 times per month) of any tobacco products other than&#xD;
             combustible cigarettes or smokeless tobacco within the last 6 months prior to&#xD;
             screening.&#xD;
&#xD;
         15. Use of any medication or substance that aids in smoking cessation, including but not&#xD;
             limited to any nicotine replacement therapy (NRT) (e.g., nicotine gum, lozenge,&#xD;
             patch), varenicline (Chantix®), bupropion (Wellbutrin®, Zyban®), or lobelia extract&#xD;
             within (≤) 30 days prior to the signing of informed consent.&#xD;
&#xD;
         16. Postpones a decision to quit using tobacco- or nicotine-containing products in order&#xD;
             to participate in this study or self-reports a previous attempt within (≤) 30 days&#xD;
             prior to the signing the informed consent.&#xD;
&#xD;
         17. Any use of aspirin (≥ 325 mg/day) or anticoagulants within (≤) 30 days prior to the&#xD;
             signing of informed consent.&#xD;
&#xD;
         18. Individuals ≥ 35 years of age currently using systemic, estrogen-containing&#xD;
             contraception or hormone replacement therapy.&#xD;
&#xD;
         19. Whole blood donation within 8 weeks (≤ 56 days) prior to the signing of informed&#xD;
             consent and between screening and check-in Day 1.&#xD;
&#xD;
         20. Plasma donation within (≤) 7 days prior to the signing of informed consent and between&#xD;
             screening and check-in Day 1.&#xD;
&#xD;
         21. Employed by a tobacco or nicotine company, the study site, or handles tobacco- or&#xD;
             nicotine-containing products as part of their job.&#xD;
&#xD;
         22. Participation in another clinical trial within (≤) 30 days prior to the signing of&#xD;
             informed consent. The 30-day window for each subject will be derived from the date of&#xD;
             the last study event in the previous study to the time of signing of informed consent&#xD;
             in the current study.&#xD;
&#xD;
         23. Drinks more than 21 servings of alcoholic beverages per week or has a positive alcohol&#xD;
             result at screening or check-in Day 1.&#xD;
&#xD;
         24. Determined by an investigator to be inappropriate for this study.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>21 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Debra Kelsh, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Altasciences Clinical Kansas, Inc.</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Altasciences Clinical Kansas, Inc.</name>
      <address>
        <city>Overland Park</city>
        <state>Kansas</state>
        <zip>66212</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>March 2021</verification_date>
  <study_first_submitted>February 11, 2021</study_first_submitted>
  <study_first_submitted_qc>February 11, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">February 16, 2021</study_first_posted>
  <last_update_submitted>March 29, 2021</last_update_submitted>
  <last_update_submitted_qc>March 29, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">March 30, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

